Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Emergent BioSolutions Q2 2024 Adj. EPS $(2.32) Misses $(0.94) Estimate, Sales $254.700M Beat $190.000M Estimate

Author: Benzinga Newsdesk | August 06, 2024 05:46pm
Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(2.32) per share which missed the analyst consensus estimate of $(0.94) by 146.81 percent. This is a 120.95 percent decrease over losses of $(1.05) per share from the same period last year. The company reported quarterly sales of $254.700 million which beat the analyst consensus estimate of $190.000 million by 34.05 percent. This is a 24.62 percent decrease over sales of $337.900 million the same period last year.

Posted In: EBS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist